Company news

Nkarta, Inc. news in 2024

Nkarta, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

December 4, 2024

Nkarta to Participate in an Upcoming Investor Conference

November 25, 2024

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

November 6, 2024

Nkarta to Participate in Upcoming Investor Conference

September 2, 2024

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

August 12, 2024

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

July 23, 2024

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

July 15, 2024

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

June 26, 2024

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

June 12, 2024

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

May 8, 2024

Nkarta to Participate in Upcoming Investor Conferences

April 2, 2024

Nkarta Announces Pricing of $240 Million Underwritten Offering

March 24, 2024

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

March 20, 2024

Decks in 2024